NewAmsterdam Pharma (NASDAQ:NAMSW) Short Interest Down 73.5% in December

NewAmsterdam Pharma (NASDAQ:NAMSW) was the recipient of a large decline in short interest in the month of December. As of December 31st, there was short interest totaling 493 shares, a decline of 73.5% from the December 15th total of 1,861 shares. Based on an average daily volume of 628 shares, the days-to-cover ratio is currently 0.8 days. Based on an average daily volume of 628 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Trading of NewAmsterdam Pharma

A hedge fund recently raised its stake in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC boosted its position in NewAmsterdam Pharma (NASDAQ:NAMSW) by 1.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 245,000 shares of the company’s stock after purchasing an additional 3,043 shares during the period. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $1,960,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

NewAmsterdam Pharma Stock Performance

NASDAQ:NAMSW traded up $0.85 during midday trading on Tuesday, hitting $23.95. 400 shares of the company traded hands, compared to its average volume of 300. The firm’s fifty day moving average is $25.92 and its 200-day moving average is $19.18. NewAmsterdam Pharma has a 12-month low of $5.45 and a 12-month high of $29.99.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.